Gracell Biotechnologies

Gracell Biotechnologies, Inc. engages in the research and development activities of biotechnological and pharmaceutical industries. The firm through its FasTCAR and TruUCAR platforms, it is developing a pipeline of autologous and allogeneic cell therapy candidates with the potential to treat both hematologic malignancies and solid tumors. The company was founded by William Wei Cao in 2017 and is headquartered in Suzhou, China.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Gracell Biotechnologies reports solid financials and advances lead CAR-T therapy

Gracell Biotechnologies showcased strong financials and promising progress with their lead CAR-T therapy GC012F for multiple myeloma.
While facing challenges in trial optimization and enrollment, the company is well-positioned to leverage partnerships and drive future growth.
Opportunities lie in expanding partnerships, generating durability data, and prioritizing pipeline development to enhance market competitiveness and patient outcomes.

Gracell Biotechnologies reports Q1 loss, advances CAR-T therapy pipeline

Gracell Biotechnologies faces financial challenges with a net loss in Q1 2023 but maintains a strong cash position for future operations.
The company's focus on advancing CAR-T therapy, particularly GC012F, and venturing into autoimmune disease clinical development highlight strategic growth initiatives.

Gracell Biotechnologies excels in Q2 with promising trial results and funding success

Gracell Biotechnologies showcased strong performance in Q2 2023 with positive trial results and successful fundraising, underlining their commitment to innovation and growth.
While facing challenges in communication and sustaining trial outcomes, the company's strategic strengths and opportunities position them for future success in the biotech sector.
Investors should take note of Gracell's progress in advancing novel therapies like GC012F and their financial stability, signaling potential for long-term value creation.

Gracell Biotechnologies reports strong Q3 performance and advances CAR-T therapies

Gracell Biotechnologies reported positive financial performance and strong clinical data, positioning the company well for future growth and innovation.
While facing challenges such as limited information availability and regulatory complexities, the company remains focused on advancing its CAR-T therapies and addressing unmet medical needs.
Opportunities lie in leveraging financial strength to attract partners, showcasing research at industry events, and advancing clinical programs for myeloma and autoimmune diseases.
Overall, Gracell Biotechnologies' emphasis on safety, efficacy, and innovation underscores its commitment to developing transformative therapies for patients in need.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the company has entered into a Manufacturing Service Agreement (MSA) with Lonza (SIX:LONN) for clinical manufacturing of Gracell's FasTCAR-enabled CAR-T cell product candidates in the U.S. Gracell is advancing its innovative CAR-T pipeline globally for difficult-to-treat cancers, including its lead program for GC012F, a BCMA/CD19 dual-targeting CAR-T therapy for multiple myeloma.

Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.

SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enrolled the first patient in their pivotal Phase 1/2 clinical study of GC007g, an allogeneic donor-derived anti-CD19 chimeric antigen receptor (CAR)-T cell therapy for the treatment of B-cell acute lymphoblastic leukemia (B-ALL). GC007g is an allogeneic HLA (human leukocyte antigen)-matched donor-derived CAR-T therapy.

Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL

SUZHOU and SHANGHAI, China, March 17, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it will participate in the upcoming 2021 Virtual Wells Fargo Biotech Corporate Access Day. Details of the event are as follows:

Gracell Biotechnologies to Participate in the 2021 Virtual Wells Fargo Biotech Corporate Access Day

Gracell Biotechnologies, Inc. (GRCL) CEO Dr. William Cao on Q4 2020 Results - Earnings Call Transcript

Reported interim readouts for lead CAR-T product candidates: FasTCAR-enabled dual-targeting BCMA/CD19 autologous CAR-T product candidate GC012F for the treatment of multiple myeloma and TruUCAR-enabled CD7-directed CAR-T product candidate GC027 for the treatment of T-ALL

Gracell Biotechnologies Reports Fourth Quarter and Fiscal Year 2020 Unaudited Financial Results and Provides Corporate Update

SUZHOU and SHANGHAI, China, Jan. 19, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that...

Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL

SUZHOU, China, Jan. 15, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted the Medical...

Gracell Biotechnologies Receives Medical Products Manufacturing Certificate for CAR-T Cell Therapy Products

SUZHOU and SHANGHAI, China, Jan. 13, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, has been granted...

China NMPA Grants Approval for the Registrational Phase 1/2 Clinical Study for GC007g - an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL

argenx

EyePoint Pharmaceuticals

Gilead Sciences

Inovio Pharmaceuticals

Eli Lilly

Paratek Pharma

Zai Lab Ltd.

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth up to $175 million in upfront and near-term payments.

Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs

Cullinan Oncology

Market for new stocks continues to be dominated by biotechnology.

Biotech IPOs Cullinan and Gracell Are Set to Start Trading

SUZHOU and SHANGHAI, China, Jan. 8, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet...

Gracell Biotechnologies Announces Pricing of Initial Public Offering

News for Gracell Biotechnologies Stock (GRCL)